Valiant Laboratories Ltd (VALIANTLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039033, "name": "Valiant Laborato", "stock_name": "Valiant Laborato", "full_name": "Valiant Laboratories Ltd", "name_url": "stocks-analysis/valiant-laborato", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "75.98", "chg": -2.52, "chgp": "-3.21%", "dir": -1, "prev_price": "78.50", "mcapval": "418.00 Cr", "mcap": "Micro Cap", "scripcode": 543998, "symbol": "VALIANTLAB", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE0JWS01017", "curr_date": "Jun 03, 03:30 PM", "curr_time": "00:22 AM", "last_traded_at": "Jun 03, 03:30 PM IST", "bse_nse_vol": "7.71 k", "exc_status": "Active", "traded_date": "Jun 03, 2026", "traded_date_str": "2026 06 03", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/valiant-laborato-10039033-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Valiant Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/valiant-laboratories-ltd-is-rated-sell-4025953", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ValiantLaborato_mojoScore_4025953.png", "date": "2026-06-01 10:10:51", "description": "Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook." }, { "title": "Valiant Laboratories Ltd Falls 0.75%: 3 Key Factors Driving the Week’s Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-ltd-falls-075-3-key-factors-driving-the-weeks-volatility-4008024", "imagepath": "", "date": "2026-05-23 11:01:01", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>18 May:</strong> Quality grade upgrade signals mixed fundamentals</p>\n <p><strong>19 May:</strong> Valuation shifts indicate heightened price risk</p>\n <p><strong>21 May:</strong> Downgrade to Strong Sell amid mixed financial and technical signals</p>\n <p><strong>22 May:</strong> Week closes at Rs.78.19 (-0.75%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.78.78</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.78.19</div><d..." }, { "title": "Valiant Laboratories Downgraded to Strong Sell Amid Mixed Financial and Technical Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/valiant-laboratories-downgraded-to-strong-sell-amid-mixed-financial-and-technical-signals-4002334", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ValiantLaborato_mojoScore_4002334.png", "date": "2026-05-21 08:28:13", "description": "Valiant Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 20 May 2026, reflecting a complex interplay of improved quarterly financials but deteriorating quality and valuation metrics, alongside mixed technical indicators. Despite a positive financial trend in the latest quarter, concerns over long-term fundamentals and expensive valuation have weighed heavily on investor sentiment." }, { "title": "Valiant Laboratories Ltd Valuation Shifts Signal Heightened Price Risk", "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-ltd-valuation-shifts-signal-heightened-price-risk-3997935", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ValiantLaborato_valuationdot_3997935.png", "date": "2026-05-19 08:02:54", "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from an already expensive rating to very expensive territory. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock has delivered mixed returns compared to the broader Sensex, prompting investors to reassess its price attractiveness amid challenging fundamentals and peer comparisons." }, { "title": "Valiant Laboratories Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals", "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-ltd-quality-grade-upgrade-signals-mixed-business-fundamentals-3995812", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ValiantLaborato_qualitydot_3995812.png", "date": "2026-05-18 08:00:12", "description": "Valiant Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as sales and EBIT growth have strengthened considerably, concerns remain around returns and capital efficiency, prompting a cautious outlook despite the upgrade." }, { "title": "Are Valiant Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-valiant-laboratories-ltd-latest-results-good-or-bad-3995058", "imagepath": "", "date": "2026-05-16 19:30:36", "description": "Valiant Laboratories Ltd reported its Q4 FY26 results, showcasing a significant increase in net sales, which reached ₹91.98 crores, reflecting a quarter-on-quarter growth of 75.33%. This marks a notable acceleration from the previous quarter's revenue of ₹52.46 crores. The net profit for the quarter was ₹1.76 crores, a recovery from a loss in the prior quarter, indicating a positive shift in profitability metrics. However, this profit was largely influenced by a favorable tax adjustment rather than a fundamental operational improvement.\n\nDespite the impressive revenue growth, the company's operating margin stood at 5.23%, which, while an improvement from a negative margin in the previous quarter, remains low compared to industry standards. The return on equity (ROE) was reported at 1.60%, highlighting ongoing challenges in capital efficiency and profitability. The five-year average ROE of 0.80% further unde..." }, { "title": "Valiant Laboratories Ltd’s 3.04% Weekly Decline: Technical Stabilisation Amid Mixed Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-ltds-304-weekly-decline-technical-stabilisation-amid-mixed-signals-3993805", "imagepath": "", "date": "2026-05-16 10:04:36", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 11:</strong> Sharp 5.00% decline on heavy market sell-off</p>\n <p><strong>May 13:</strong> Rebound with 4.56% gain amid stabilising market</p>\n <p><strong>May 15:</strong> Quarterly results reveal strong turnaround; technical rating upgraded to Sell</p>\n <p><strong>May 15:</strong> Stock closes at Rs.78.78, down 3.92% on the day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.81.25</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-va..." }, { "title": "Valiant Laboratories Q4 FY26: Profit Recovery Masks Deeper Operational Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/valiant-laboratories-q4-fy26-profit-recovery-masks-deeper-operational-concerns-3993408", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ValiantLaborato_quaterlyResult_3993408.png", "date": "2026-05-15 17:20:35", "description": "Valiant Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹432.00 crores, reported a net profit of ₹1.76 crores for Q4 FY26, marking a dramatic recovery from the ₹7.06 crore loss in the previous quarter. However, the apparent turnaround conceals troubling operational realities that warrant investor caution, with the stock declining 3.92% to ₹78.78 following the results announcement." }, { "title": "Valiant Laboratories Ltd Reports Strong Quarterly Turnaround Amid Market Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-ltd-reports-strong-quarterly-turnaround-amid-market-challenges-3992746", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ValiantLaborato_fintrenddot_3992746.png", "date": "2026-05-15 11:00:34", "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s latest results reveal significant growth in revenue and profitability metrics, marking a positive shift from its previously flat financial trend and improving its Mojo Grade from Strong Sell to Sell." } ], "total": 315, "sid": "10039033", "stock_news_url": "https://www.marketsmojo.com/news/valiant-laboratories-10039033" }, "announcements": [ { "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015", "datetime": "30-May-2026", "details": "Please find enclosed", "source": "BSE" }, { "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance", "datetime": "22-May-2026", "details": "Annual Secretarial Compliance Report for the Financial Year 2025-2026.", "source": "BSE" }, { "caption": "Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011", "datetime": "20-May-2026", "details": "The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Valiant Organics Ltd", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Valiant Laboratories Ltd has announced <strong>1:4</strong> rights issue, ex-date: 18 Jul 25", "dt": "2025-07-18", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

May 11: Sharp 5.00% decline on heavy market sell-off

May 13: Rebound with 4.56% gain amid stabilising market

May 15: Quarterly results reveal strong turnaround; technical rating upgraded to Sell

May 15: Stock closes at Rs.78.78, down 3.92% on the day

Week Open

Rs.81.25

Week Close

Read full news article

Valiant Laboratories Q4 FY26: Profit Recovery Masks Deeper Operational Concerns

2026-05-15 17:20:35

Valiant Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹432.00 crores, reported a net profit of ₹1.76 crores for Q4 FY26, marking a dramatic recovery from the ₹7.06 crore loss in the previous quarter. However, the apparent turnaround conceals troubling operational realities that warrant investor caution, with the stock declining 3.92% to ₹78.78 following the results announcement.

Read full news article

Valiant Laboratories Ltd Reports Strong Quarterly Turnaround Amid Market Challenges

2026-05-15 11:00:34

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s latest results reveal significant growth in revenue and profitability metrics, marking a positive shift from its previously flat financial trend and improving its Mojo Grade from Strong Sell to Sell.

Read full news article